Psychedelics Show Promise for Treating Neuropsychiatric Disorders
Psilocybin is a hallucinogenic/psychedelic substance that works by activating serotonin receptors in the prefrontal cortex, the area of the brain that affects mood, cognition, and perception. Recently, psychedelics have shown acceptable safety and efficacy in treating various neuropsychiatric disorders. They have also demonstrated sustained prosocial behavior and helped with social cognition deficits related to autism. Due to its potential therapeutic benefits, psilocybin is now being recognized by the investment world as a possible revolutionary treatment for the autism community. Market analysts claim that the current autism therapeutics market is valued at $3.2 billion. However, it is projected to hit $4.6 billion by 2026. While the autism community is watching the development of any and every new possible treatment for the disorder, the market analysts and investors are keeping a close eye on the pharmaceutical companies developing psilocybin for future investment opportunities.
